Zacks: Brokerages Expect Radius Health Inc (NASDAQ:RDUS) Will Announce Quarterly Sales of $45.67 Million

Wall Street analysts expect Radius Health Inc (NASDAQ:RDUS) to announce sales of $45.67 million for the current quarter, Zacks reports. Four analysts have provided estimates for Radius Health’s earnings. The highest sales estimate is $46.06 million and the lowest is $45.00 million. Radius Health posted sales of $27.64 million during the same quarter last year, which suggests a positive year-over-year growth rate of 65.2%. The firm is expected to report its next earnings report on Thursday, November 7th.

On average, analysts expect that Radius Health will report full-year sales of $168.65 million for the current fiscal year, with estimates ranging from $167.47 million to $170.07 million. For the next fiscal year, analysts anticipate that the business will post sales of $231.93 million, with estimates ranging from $205.71 million to $243.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Radius Health.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.09. Radius Health had a negative net margin of 127.22% and a negative return on equity of 368.58%. The company had revenue of $41.04 million for the quarter, compared to the consensus estimate of $40.60 million. During the same period in the previous year, the firm earned ($0.99) earnings per share. The firm’s revenue for the quarter was up 81.4% on a year-over-year basis.

Several research analysts recently commented on RDUS shares. Morgan Stanley started coverage on shares of Radius Health in a research note on Thursday, September 5th. They issued a “buy” rating and a $43.00 target price on the stock. BidaskClub downgraded shares of Radius Health from a “buy” rating to a “hold” rating in a research note on Thursday, October 3rd. Cowen reaffirmed a “hold” rating on shares of Radius Health in a research note on Thursday, August 8th. ValuEngine downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Finally, Citigroup upgraded shares of Radius Health from a “neutral” rating to a “buy” rating and lifted their price target for the company from $24.00 to $40.00 in a report on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $36.50.

Shares of NASDAQ RDUS traded up $0.18 during mid-day trading on Friday, hitting $24.53. The stock had a trading volume of 407,962 shares, compared to its average volume of 728,224. The company has a debt-to-equity ratio of 6.75, a quick ratio of 4.28 and a current ratio of 4.38. Radius Health has a 1 year low of $12.81 and a 1 year high of $29.97. The business has a 50 day moving average price of $26.62 and a two-hundred day moving average price of $23.13. The firm has a market cap of $1.09 billion, a P/E ratio of -5.03 and a beta of 0.78.

Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new stake in Radius Health in the second quarter valued at $34,000. Captrust Financial Advisors bought a new stake in Radius Health in the second quarter valued at $38,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Radius Health by 3,130.7% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,423 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 2,348 shares in the last quarter. Quantamental Technologies LLC bought a new stake in Radius Health in the second quarter valued at $62,000. Finally, SG Americas Securities LLC bought a new stake in Radius Health in the first quarter valued at $157,000.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Recommended Story: Do investors pay a separate front-end load every time they buy additional shares?

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.